Woodard & Co. Asset Management Group Inc. ADV Increases Stake in Johnson & Johnson (NYSE:JNJ)

Woodard & Co. Asset Management Group Inc. ADV increased its holdings in Johnson & Johnson (NYSE:JNJ) by 5.0% during the third quarter, Holdings Channel.com reports. The firm owned 21,330 shares of the company’s stock after acquiring an additional 1,013 shares during the quarter. Johnson & Johnson accounts for 0.8% of Woodard & Co. Asset Management Group Inc. ADV’s investment portfolio, making the stock its 28th largest holding. Woodard & Co. Asset Management Group Inc. ADV’s holdings in Johnson & Johnson were worth $3,457,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Investment Research & Advisory Group Inc. lifted its position in Johnson & Johnson by 1.3% in the third quarter. Investment Research & Advisory Group Inc. now owns 14,968 shares of the company’s stock valued at $2,426,000 after purchasing an additional 189 shares during the last quarter. apricus wealth LLC increased its stake in shares of Johnson & Johnson by 2.4% in the third quarter. apricus wealth LLC now owns 13,791 shares of the company’s stock worth $2,235,000 after buying an additional 322 shares during the period. Mcdaniel Terry & Co. boosted its position in Johnson & Johnson by 2.0% during the 3rd quarter. Mcdaniel Terry & Co. now owns 185,003 shares of the company’s stock valued at $29,982,000 after buying an additional 3,571 shares during the period. Assenagon Asset Management S.A. grew its holdings in Johnson & Johnson by 8.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 87,476 shares of the company’s stock worth $14,176,000 after acquiring an additional 6,642 shares during the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC increased its position in shares of Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after acquiring an additional 91 shares during the period. 69.55% of the stock is owned by institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Sanford C. Bernstein raised their target price on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Royal Bank of Canada lifted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. TD Cowen cut their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Finally, Citigroup raised their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Six equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $175.93.

Johnson & Johnson Price Performance

Shares of JNJ opened at $160.88 on Friday. The firm’s 50-day simple moving average is $163.38 and its two-hundred day simple moving average is $154.98. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The stock has a market cap of $387.28 billion, a PE ratio of 23.28, a price-to-earnings-growth ratio of 2.90 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.46% and a net margin of 19.14%. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same quarter last year, the company earned $2.66 EPS. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.